Vor Biopharma (VOR) Accumulated Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Accumulated Expenses data on file, last reported at $14.7 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $14.7 million, up 701.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.7 million (up 701.69% YoY), and the FY2025 annual result was $19.8 million, up 237.73% from the prior year.
• Accumulated Expenses eased to $14.7 million in Q1 2026 per VOR's latest filing, from $19.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $19.8 million in Q4 2025 and troughed at $1.8 million in Q1 2025.
• A 5-year average of $6.6 million and a median of $5.5 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses sank 65.82% in 2025, then jumped 701.69% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $4.4 million in 2022, then soared by 35.25% to $6.0 million in 2023, then slipped by 1.85% to $5.9 million in 2024, then surged by 237.73% to $19.8 million in 2025, then retreated by 25.49% to $14.7 million in 2026.
• Business Quant data shows VOR's Accumulated Expenses at $14.7 million in Q1 2026, $19.8 million in Q4 2025, and $3.0 million in Q3 2025.